Quarterly report · Q3
7745.TEDINET S100Q869
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥42.2bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥51.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥37.3bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥4.7bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥3.6bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥4.9bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.7bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥4.9bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.6bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.5bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.2bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.5bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥2.5bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥68.1bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥59.2bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥57.2bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥37.2bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥32.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥30.9bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥27.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥25.4bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥14.4bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥11.9bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥128.43 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.97 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥172.92 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥104.55 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.52 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥128.31 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥172.66 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥104.38 | 2021-04-01 → 2021-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 45.2% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.8% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.6% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 98
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥21.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥21.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥1.9bn |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥4.7bn |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥4.4bn |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥352m |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥486m |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥6.8bn |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥6.8bn |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥1m |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥31m |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥6.3bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥2.5bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥451m |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥7.4bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥328m |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥7.0bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥242m |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥730m |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥729m |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥0 |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥102m |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥7.2bn |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥7.2bn |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥3m |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥13.8bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥11.0bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥2.9bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥541m |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥4.1bn |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥9.0bn |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.3bn |
| jpcrp040300-q3r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.3bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥25.6bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥19.9bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥5.8bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥34.5bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥18.4bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥16.1bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.3bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥18.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥18.1bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥1.5bn |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥2.9bn |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥2.7bn |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥177m |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥221m |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥5.5bn |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥5.5bn |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥10m |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥135m |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥3.2bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥2.0bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥345m |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥6.2bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥394m |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥5.8bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥308m |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥696m |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥696m |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥0 |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥43m |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥6.0bn |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥6.0bn |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥4m |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥875m |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥13.6bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥11.2bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥2.4bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥223m |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥11.8bn |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥4.2bn |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥7.6bn |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥1.9bn |
| jpcrp040300-q3r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥3.5bn |
| jpcrp040300-q3r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥3.5bn |
| jpcrp040300-q3r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥1.1bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥22.4bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥17.8bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥4.6bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥833m |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥29.5bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥16.1bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥13.5bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥3.2bn |
| jpcrp040300-q3r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥3.5bn |
| jpcrp040300-q3r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥3.5bn |
| jpcrp040300-q3r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥1.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 456
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for product warranties | Prior1YearInstant | 183000000 | JPY |
| Provision for product warranties | CurrentQuarterInstant | 212000000 | JPY |
| Other cl | Prior1YearInstant | 4285000000 | JPY |
| Other cl | CurrentQuarterInstant | 6798000000 | JPY |
| Current liabilities | Prior1YearInstant | 26202000000 | JPY |
| Current liabilities | CurrentQuarterInstant | 31725000000 | JPY |
| Bonds payable | Prior1YearInstant | 500000000 | JPY |
| Bonds payable | CurrentQuarterInstant | － | JPY |
| Long term loans payable | Prior1YearInstant | 3813000000 | JPY |
| Long term loans payable | CurrentQuarterInstant | 3394000000 | JPY |
| Provision for product warranties ncl | Prior1YearInstant | 49000000 | JPY |
| Provision for product warranties ncl | CurrentQuarterInstant | 48000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 1034000000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 1021000000 | JPY |
| Provision for share based remuneration for directors and other officers ncl | Prior1YearInstant | 83000000 | JPY |
| Provision for share based remuneration for directors and other officers ncl | CurrentQuarterInstant | 84000000 | JPY |
| Other ncl | Prior1YearInstant | 514000000 | JPY |
| Other ncl | CurrentQuarterInstant | 949000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 5995000000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 5499000000 | JPY |
| Liabilities | Prior1YearInstant | 32198000000 | JPY |
| Liabilities | CurrentQuarterInstant | 37224000000 | JPY |
| Capital stock | Prior1YearInstant | 6388000000 | JPY |
| Capital stock | CurrentQuarterInstant | 6388000000 | JPY |
| Capital surplus | Prior1YearInstant | 6413000000 | JPY |
| Capital surplus | CurrentQuarterInstant | 8318000000 | JPY |
| Retained earnings | Prior1YearInstant | 14367000000 | JPY |
| Retained earnings | CurrentQuarterInstant | 17141000000 | JPY |
| Treasury stock | Prior1YearInstant | -1044000000 | JPY |
| Treasury stock | CurrentQuarterInstant | -171000000 | JPY |
| Shareholders equity | Prior1YearInstant | 26125000000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 31677000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 26000000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 25000000 | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | -2278000000 | JPY |
| Foreign currency translation adjustment | CurrentQuarterInstant | -1117000000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 282000000 | JPY |
| Remeasurements of defined benefit plans | CurrentQuarterInstant | 212000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | -1969000000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | -880000000 | JPY |
| Non controlling interests | Prior1YearInstant | 2885000000 | JPY |
| Non controlling interests | CurrentQuarterInstant | 104000000 | JPY |
| Net assets | Prior1YearInstant | 27041000000 | JPY |
| Net assets | CurrentQuarterInstant | 30901000000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 59239000000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 68125000000 | JPY |
| Net sales | Prior1YTDDuration | 37325000000 | JPY |
| Net sales | CurrentYTDDuration | 42217000000 | JPY |
| Cost of sales | Prior1YTDDuration | 20984000000 | JPY |
| Cost of sales | CurrentYTDDuration | 23432000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |